New Chemo-Light cocktail offers hope for elderly lymphoma patients
NCT ID NCT05798156
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a chemotherapy-light combination of three drugs—rituximab, polatuzumab vedotin, and glofitamab—in 125 patients over 60 with aggressive B-cell lymphoma who cannot tolerate full-dose standard chemo. The goal is to see if this gentler approach can control the disease and improve survival without harsh side effects. Results will guide future development of this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab, polatuzumab vedotin, and glofitamab
- What this could lead to
- If successful, this could offer a gentler, effective treatment option for older or frail patients with aggressive B-cell lymphoma who cannot handle standard chemotherapy.
- What could go wrong
- This is a phase 2 trial with only 125 participants, so results are preliminary. The combination may not work as well as hoped, and side effects from the drugs could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AKH Meduni Wien
Vienna, Austria
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Ev. Klinikum Essen-Mitte
Essen, Germany
-
HELIOS Klinikum Berlin-Buch
Berlin, Germany
-
Hanusch Krankenhaus
Vienna, Austria
-
Kepler Universitätsklinikum
Linz, Austria
-
Klinikum Chemnitz
Chemnitz, Germany
-
Klinikum Ludwigshafen
Ludwigshafen, 67063, Germany
-
Kreiskliniken Reutlingen
Reutlingen, Germany
-
Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Salzburg, Austria
-
Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum
Bochum, Germany
-
Ordensklinikum Linz - Barmherzige Schwestern
Linz, Austria
-
Ordensklinikum Linz - Elisabethinen
Linz, Austria
-
Ortenauklinikum Offenburg-Kehl
Offenburg, Germany
-
TU München (rechts des Isar)
München, Germany
-
Uniklinik Innsbruck
Innsbruck, Austria
-
Uniklinikum Düsseldorf
Düsseldorf, Germany
-
Univ. Klinikum St. Pölten
Sankt Pölten, Austria
-
University Hospital Jena
Jena, Germany
-
Universitätsklinikum Erlangen
Erlangen, Germany
-
Universitätsklinikum Halle
Halle, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Magdeburg
Magdeburg, Saxony-Anhalt, 39120, Germany
-
Universitätsklinikum Regensburg
Regensburg, Germany
-
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany
-
Universitätsklinikum Würzburg
Würzburg, Germany
-
Unversitätsklinikum Münster
Münster, 48149, Germany
-
Westdeutsches Tumorzentrum Essen
Essen, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET scan targets hidden cancers with precision
- New immunotherapy MK-1045 takes on tough lymphomas
- New drug cocktail shows promise for Tough-to-Treat lymphoma
- New hope for tough lymphomas: experimental drug shows promise in Mid-Stage trial
- New vaccine strategy aims to shield lymphoma patients from deadly infections
- New pill shows promise for Hard-to-Treat leukemia and lymphoma